Award

National Institute of Allergy and Infectious Diseases 5R21AI169111-02

A novel c-di-AMP-based recombinant BCG vaccine

Recipient

Albany Medical College, Albany, NY

Award Amount

$203,750.00

Ceiling

$203,750.00

Awarded

February 01, 2024

Identifier

5R21AI169111-02

Development of a recombinant BCG vaccine secreting c-di-AMP to enhance immune response and protection against tuberculosis, aiming to improve vaccine efficacy and reduce TB incidence globally.

Description

This project aims to construct recombinant BCG strains that secrete c-di-AMP and induce IFN-I in the vaccinated host, potentially improving BCG's efficacy against tuberculosis. The research could lead to a more effective TB vaccine, significantly impacting public health by reducing TB incidence.

View original record